Published in Curr Med Res Opin on August 08, 2013
Metabolic effects of smoking cessation. Nat Rev Endocrinol (2016) 1.42
Periodontal disease and metabolic syndrome: a qualitative critical review of their association. Arch Oral Biol (2014) 0.87
Translational research in nephrology: chronic kidney disease prevention and public health. Clin Kidney J (2015) 0.81
Lifetime Smoking History and Cause-Specific Mortality in a Cohort Study with 43 Years of Follow-Up. PLoS One (2016) 0.79
Aryl hydrocarbon receptor (AhR)-dependent regulation of pulmonary miRNA by chronic cigarette smoke exposure. Sci Rep (2017) 0.75
Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study. Open Cardiovasc Med J (2016) 0.75
Elevated Blood Pressure and Serum γ -Glutamyltransferase as Significant Characteristics of Smokers With Chronic Kidney Disease. Nephrourol Mon (2014) 0.75
A Review of Epigenetic Markers of Tobacco and Alcohol Consumption. Behav Sci Law (2015) 0.75
COMMENTARY: Passive Smoking as an Independent Risk Factor for Gestational Diabetes that Synergizes with Pre-pregnancy Obesity in Urban Chinese Women. Diabetes Metab Res Rev (2017) 0.75
Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet (2012) 6.29
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet (2008) 2.53
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens (2010) 2.14
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 2.13
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Time for new indications for statins? Med Sci Monit (2009) 1.87
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Exercise capacity and mortality in older men: a 20-year follow-up study. Circulation (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. Arthritis Rheum (2011) 1.46
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood (2010) 1.44
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Ann Hematol (2004) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors? Ann Allergy Asthma Immunol (2007) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care (2012) 1.14
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
Platelet activation during exercise is not attenuated by inhibition of the renin-angiotensin system: the role of physical activity. J Hypertens (2013) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08
Exercise capacity and progression from prehypertension to hypertension. Hypertension (2012) 1.08
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
Macro and microcirculation damage and incident hypertension: predictors of progression? J Hypertens (2014) 1.07
Cold temperature and cardiovascular mortality. Circ J (2013) 1.07
The effect of smoking on arterial stiffness. Hypertens Res (2010) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Statins: a sine qua non of the management of patients with abdominal aortic aneurysms. Int J Cardiol (2013) 1.06
Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. Circ J (2013) 1.06
Metabolic syndrome in clinical practice. Cardiol J (2014) 1.06
Serum uric acid as an independent predictor of early death after acute stroke. Circ J (2007) 1.06
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04
An update on biomarkers of heart failure in hypertensive patients. J Hypertens (2012) 1.04
The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res (2009) 1.03
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem (2003) 1.03
Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens (2008) 1.03
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01